Nestle buys US medical nutrition Co Pamlab
Swiss food giant Nestle said Tuesday that it had acquired Pamlab, a
US-based company specialised in medical nutrition, as the company pushes
further into what it considers a growth segment. Nestle, which did not
disclose the value of the deal, said the acquisition was carried out by
its fully-owned subsidiary Nestle Health Science.
Medical nutritions is one of Nestle's growth-drivers and the Pamlab
acquisition follows several buys in the field in 2012, including the
purchase of Acera, a US company that specialises in nutrition for
patients with Alzheimers disease.
“The acquisition of the Pamlab business is aligned with our strategic
ambition to provide science-based nutritional solutions for people with
chronic medical conditions,” said Luis Cantarell, president and chief
executive of Nestle Health Science, in a statement. “Pamlab will
particularly strengthen our brain health platform and provide us an
additional foothold in metabolic health in the US,” he added.
Pamlab's portfolio includes product formulated to meet the
nutritional requirements of patients with diabetes to help restore the
metabolic processes associated with the condition of peripheral
neuropathy.
The serious condition is common among those with Type 2 Diabetes,
where the patient's peripheral blood flow has been compromised and their
nerves damaged.
|